Finance: A drugmaker that's taking an unconventional approach to cancer drugs just got a $1.5 billion endorsement

14 November 2017, 15:35 UTC

Loxo Oncology is building drugs that act on cancerous genetic mutations rather than the type of cancer a person has.

More details